These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 19394132)

  • 21. Percent free PSA as an additional measure in a prostate cancer screen.
    Miele ME
    Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Best screening tests for prostate cancer.
    Moul JW
    West J Med; 1998 Aug; 169(2):109-10. PubMed ID: 9735692
    [No Abstract]   [Full Text] [Related]  

  • 23. Prostate cancer: current evidence weighs against population screening.
    Boyle P; Brawley OW
    CA Cancer J Clin; 2009; 59(4):220-4. PubMed ID: 19564244
    [No Abstract]   [Full Text] [Related]  

  • 24. Efficacy vs effectiveness in prostate-specific antigen screening.
    Albertsen PC
    J Natl Cancer Inst; 2010 Mar; 102(5):288-9. PubMed ID: 20142583
    [No Abstract]   [Full Text] [Related]  

  • 25. Prostate cancer screening "reloaded".
    Gomella LG
    Can J Urol; 2010 Apr; 17(2):5057. PubMed ID: 20398441
    [No Abstract]   [Full Text] [Related]  

  • 26. Prostate-specific antigen testing. Should we recommend it?
    Hickey J
    Can Fam Physician; 2003 Mar; 49():303-4. PubMed ID: 12675542
    [No Abstract]   [Full Text] [Related]  

  • 27. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial.
    Andriole GL; Levin DL; Crawford ED; Gelmann EP; Pinsky PF; Chia D; Kramer BS; Reding D; Church TR; Grubb RL; Izmirlian G; Ragard LR; Clapp JD; Prorok PC; Gohagan JK;
    J Natl Cancer Inst; 2005 Mar; 97(6):433-8. PubMed ID: 15770007
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incidental acute prostatic inflammation is associated with a lower percentage of free prostate-specific antigen than other benign conditions of the prostate: a prospective screening study.
    Rowe EW; Laniado ME; Walker MM; Anup P
    BJU Int; 2006 May; 97(5):1039-42. PubMed ID: 16643488
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Screening for prostate cancer--the controversy that refuses to die.
    Barry MJ
    N Engl J Med; 2009 Mar; 360(13):1351-4. PubMed ID: 19297564
    [No Abstract]   [Full Text] [Related]  

  • 30. Early detection of prostate cancer. Recommendations from the Canadian Urological Association.
    Ramsey EW
    Can J Oncol; 1994 Nov; 4 Suppl 1():82-5. PubMed ID: 8853498
    [No Abstract]   [Full Text] [Related]  

  • 31. Screening for prostate cancer: estimating the magnitude of overdetection.
    McGregor M; Hanley JA; Boivin JF; McLean RG
    CMAJ; 1998 Dec; 159(11):1368-72. PubMed ID: 9861205
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Screening and early detection for prostate cancer.
    Magoha GA
    East Afr Med J; 1997 Oct; 74(10):664-7. PubMed ID: 9529752
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Prostate cancer screening using prostate specific antigen (PSA) in Tokatsu Hospital--examination of lost-to-followup cases].
    Shimizu N; Yamanaka H; Ichinose Y; Saitou Y
    Hinyokika Kiyo; 1998 Mar; 44(3):155-8. PubMed ID: 9589875
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostate cancer screening.
    Catalona WJ
    BJU Int; 2004 Nov; 94(7):964-6. PubMed ID: 15541107
    [No Abstract]   [Full Text] [Related]  

  • 35. PSA and prostate cancer screening: the challenge of the new millennium.
    Bjartell A
    Eur Urol; 2007 Nov; 52(5):1284-6. PubMed ID: 17720305
    [No Abstract]   [Full Text] [Related]  

  • 36. Ten year trend in prostate cancer screening with high prostate-specific antigen exposure rate in Japan.
    Okihara K; Kitamura K; Okada K; Mikami K; Ukimura O; Miki T
    Int J Urol; 2008 Feb; 15(2):156-60; discussion 161. PubMed ID: 18269453
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does screening with prostate/specific antigen improve outcomes?
    Ohrt D
    Minn Med; 1996 Apr; 79(4):50-1. PubMed ID: 8637494
    [No Abstract]   [Full Text] [Related]  

  • 38. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
    Roobol MJ; Roobol DW; Schröder FH
    Urology; 2005 Feb; 65(2):343-6. PubMed ID: 15708050
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Application of prostate-specific antigen in prostate cancer.
    Liang SL
    MLO Med Lab Obs; 2008 Oct; 40(10):54, 56-7. PubMed ID: 18988558
    [No Abstract]   [Full Text] [Related]  

  • 40. Rebuttal: Should Canadians be offered systematic prostate cancer screening? NO.
    Labrecque M; Légaré F; Cauchon M
    Can Fam Physician; 2007 Jul; 53(7):1140-3. PubMed ID: 17872800
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.